Omnicell (NASDAQ:OMCL) Raised to Buy at Wall Street Zen

Key Points

• Wall Street Zen upgraded Omnicell (OMCL) from "hold" to "buy", joining other analysts so that seven rate it Buy, one Hold and one Sell, with a consensus "Moderate Buy" and an average price target of $59.86.
• Omnicell beat Q1 expectations, reporting $0.55 EPS vs. $0.33 expected and revenue of $309.88 million (up 14.9% year-over-year), and set FY2026 guidance of $1.80–$2.00 EPS.
• Insider and institutional activity: an EVP sold 7,405 shares in March; insiders own 2.92% while institutional investors hold 97.7% of the stock, with several funds (e.g., AQR, Jane Street, UBS AM) increasing positions recently.

Omnicell (NASDAQ:OMCL - Get Free Report) was upgraded by equities research analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a report issued on Saturday.

A number of other equities research analysts also recently issued reports on OMCL. UBS Group set a $60.00 price target on shares of Omnicell and gave the company a "buy" rating in a research report on Friday, March 13th. Wells Fargo & Company lifted their price target on shares of Omnicell from $52.00 to $55.00 and gave the company an "overweight" rating in a research report on Thursday, April 23rd. Piper Sandler reiterated an "overweight" rating and set a $49.00 price target (down from $63.00) on shares of Omnicell in a research report on Friday, February 6th. Craig Hallum reiterated a "buy" rating and set a $55.00 price target on shares of Omnicell in a research report on Wednesday. Finally, Zacks Research upgraded shares of Omnicell from a "strong sell" rating to a "hold" rating in a research report on Tuesday, March 10th. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $59.86.

Omnicell Price Performance

Shares of OMCL opened at $42.80 on Friday. Omnicell has a twelve month low of $22.66 and a twelve month high of $55.00. The stock's 50 day moving average is $37.16 and its two-hundred day moving average is $39.44. The firm has a market capitalization of $1.95 billion, a PE ratio of 97.27, a P/E/G ratio of 1.51 and a beta of 0.96. The company has a current ratio of 1.50, a quick ratio of 1.22 and a debt-to-equity ratio of 0.13.

Omnicell (NASDAQ:OMCL - Get Free Report) last announced its quarterly earnings data on Tuesday, April 28th. The company reported $0.55 earnings per share for the quarter, beating analysts' consensus estimates of $0.33 by $0.22. Omnicell had a return on equity of 4.00% and a net margin of 1.67%.The company had revenue of $309.88 million for the quarter, compared to analyst estimates of $304.02 million. During the same quarter in the previous year, the company earned $0.26 EPS. The firm's revenue for the quarter was up 14.9% compared to the same quarter last year. Omnicell has set its FY 2026 guidance at 1.800-2.000 EPS and its Q2 2026 guidance at 0.400-48.000 EPS. Research analysts anticipate that Omnicell will post 0.92 earnings per share for the current year.

Insider Activity

In other news, EVP Corey J. Manley sold 7,405 shares of Omnicell stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $34.69, for a total transaction of $256,879.45. Following the completion of the sale, the executive vice president directly owned 96,717 shares in the company, valued at approximately $3,355,112.73. This trade represents a 7.11% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 2.92% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of OMCL. AQR Capital Management LLC raised its position in shares of Omnicell by 42.1% during the 1st quarter. AQR Capital Management LLC now owns 17,936 shares of the company's stock worth $627,000 after purchasing an additional 5,311 shares during the last quarter. Empowered Funds LLC raised its position in shares of Omnicell by 14.3% during the 1st quarter. Empowered Funds LLC now owns 9,953 shares of the company's stock worth $348,000 after purchasing an additional 1,243 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of Omnicell by 4.1% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 124,047 shares of the company's stock worth $4,337,000 after purchasing an additional 4,866 shares during the last quarter. Jane Street Group LLC raised its position in shares of Omnicell by 201.5% during the 1st quarter. Jane Street Group LLC now owns 163,664 shares of the company's stock worth $5,722,000 after purchasing an additional 109,382 shares during the last quarter. Finally, Creative Planning raised its position in shares of Omnicell by 16.7% during the 2nd quarter. Creative Planning now owns 9,390 shares of the company's stock worth $276,000 after purchasing an additional 1,347 shares during the last quarter. 97.70% of the stock is currently owned by institutional investors and hedge funds.

Omnicell Company Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company's offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell's analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.